Understanding cisplatin resistance using cellular models.
about
Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the LiteraturePathophysiological Functions of Rnd3/RhoEReview of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatmentsTCRP1 contributes to cisplatin resistance by preventing Pol β degradation in lung cancer cellsAn integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencingTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerIt's all in a day's work: Regulation of DNA excision repair by the circadian clock.p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell.USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response.Nucleotide excision repair in Trypanosoma brucei: specialization of transcription-coupled repair due to multigenic transcriptionAnvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines.Benzene-poly-carboxylic acid complex, a novel anti-cancer agent induces apoptosis in human breast cancer cells.Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT)Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway.Understanding drugs in breast cancer through drug sensitivity screeningPolymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.Asperolide A, a marine-derived tetranorditerpenoid, induces G2/M arrest in human NCI-H460 lung carcinoma cells, is mediated by p53-p21 stabilization and modulated by Ras/Raf/MEK/ERK signaling pathway.Post-transcriptional controls by ribonucleoprotein complexes in the acquisition of drug resistance.Wentilactone A as a novel potential antitumor agent induces apoptosis and G2/M arrest of human lung carcinoma cells, and is mediated by HRas-GTP accumulation to excessively activate the Ras/Raf/ERK/p53-p21 pathway.In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.Down-regulation of ALKBH2 increases cisplatin sensitivity in H1299 lung cancer cells.Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer.Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.Effect of all-trans retinoic acid on the growth of two nasopharyngeal cancer cell lines and its treatment potential in combination with cisplatin.Redox-dependent modulation of metformin contributes to enhanced sensitivity of esophageal squamous cell carcinoma to cisplatin.Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective.Synthetic β-nitrostyrene derivative CYT-Rx20 as inhibitor of oral cancer cell proliferation and tumor growth through glutathione suppression and reactive oxygen species induction.Metabolism of cisplatin in the organs of Rattus norvegicus: role of Glutathione S-transferase P1.The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.Association ofHMGB1andHMGB2genetic polymorphisms with lung cancer chemotherapy responseThe ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patientsThe Network of Non-coding RNAs in Cancer Drug Resistance
P2860
Q26766244-02EBABD8-CC01-474D-9F7D-4C4319200B0DQ28078292-B5400DF9-2555-4818-9574-CD196F50D1F5Q28082382-F5728305-0C7F-45A7-ADE0-8D4E3F70C3A8Q28118898-C97C9328-8475-451A-BDF7-9E6AC985806BQ28390823-554E1D47-2E42-4D27-B988-079D3DF9A20BQ28396304-46D89943-CC5B-498E-BA82-4D753FA7AA1AQ33412057-007F1721-306E-4AA2-BC1A-DC7C0CBD35B0Q33750796-50F58018-FA78-4C35-94D3-4BED209DBE87Q33770883-11CBDBED-3AD7-4C87-9E60-68E92DB57CC8Q34069546-897AD042-9CAC-4148-9BEF-77B83EB7364EQ34632511-962DECC6-DB4C-4633-999F-DFE9449ABC70Q35093497-14468802-B194-4120-90CA-0F8D5D1BC642Q35932794-40F5CF13-5659-41A9-A4C0-D1337CC98005Q36085637-7DC5C2CA-ACE1-401F-9692-97CB1465AFFDQ36094088-02911D55-9CF5-49A8-9326-6C9BE48F36E2Q36234079-31F9F5DA-12B1-4E1A-BC9E-7F027FBEFADEQ36360770-3F4438EC-C69C-460D-9768-16545059C279Q36790826-71B91562-6A1F-423F-B163-03EC23FF5A1CQ36806673-9E7BFA03-1663-4596-8528-02490CEAF217Q37139289-8092B2ED-4AE4-43B3-9E6F-48391F251274Q37424084-887CEBA6-36E1-4AA4-9B60-5045CF75E242Q37621597-A42A823B-14EA-4669-A3C9-8F9C8699896CQ37728844-5089A27D-CF15-4AF5-AA5F-9C34EA6E2CF5Q37996270-5278A8DF-D331-4542-8231-029EDE70485DQ39131399-CE84F7DE-7C83-4D1B-B22D-E6420410A903Q39335891-F8870310-23A1-4480-819C-1799D29D8364Q42365321-501FA01B-191B-485F-A153-931AAB732E1FQ44242635-AC7C59F3-19A1-440B-97B7-E0E796B18637Q46396027-3EC14BD9-6B16-4A91-9EEB-2C3AD96A124AQ53298155-790598D8-142F-4970-BC24-886A5E4E9F3EQ55181875-977D5B91-770D-4040-B4CD-BCF01EB66A15Q57500224-6AABDC8D-1B77-4BE4-9C15-3B8EE37354B5Q57500237-C848DEF8-44E4-48DF-9EAA-76562308AF52Q58694197-871D44DE-CFAD-400B-A9BD-92AB1CDA4205
P2860
Understanding cisplatin resistance using cellular models.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Understanding cisplatin resistance using cellular models.
@ast
Understanding cisplatin resistance using cellular models.
@en
Understanding cisplatin resistance using cellular models.
@nl
type
label
Understanding cisplatin resistance using cellular models.
@ast
Understanding cisplatin resistance using cellular models.
@en
Understanding cisplatin resistance using cellular models.
@nl
prefLabel
Understanding cisplatin resistance using cellular models.
@ast
Understanding cisplatin resistance using cellular models.
@en
Understanding cisplatin resistance using cellular models.
@nl
P1433
P1476
Understanding cisplatin resistance using cellular models.
@en
P2093
Britta Stordal
Mary Davey
P304
P356
10.1080/15216540701636287
P577
2007-11-01T00:00:00Z